Partner Headlines - GSK

  1. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  2. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  3. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  4. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  5. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  6. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  7. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  8. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  9. Axovant IPO Best In 20 Years

    IBD
  10. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  11. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  12. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  13. Perrigo buys Glaxo OTC drugs

    IBD
  14. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  15. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  16. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  17. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  18. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  19. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  20. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  21. Glaxo more bullish than Q1

    IBD
  22. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  23. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  24. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  25. GlaxoSmithKline

    IBD
  26. Novartis EPS beats the Street

    IBD
  27. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  28. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  29. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  30. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  31. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  32. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  33. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  34. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  35. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  36. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  37. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  38. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  39. Benzinga's Weekend M&A Chatter

    Benzinga
  40. Gilead Sciences Still has More Upside

    GuruFocus
  41. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  42. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  43. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  44. Isis Pharma To Develop GI Drugs With J&J

    IBD
  45. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  46. Ebola Drug Work Continues

    IBD
  47. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  48. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  49. Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR

    GuruFocus
  50. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga
  51. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  52. Merck Bets $9.5 Billion On Cubist's War On Superbugs

    IBD
  53. GlaxoSmithKline's Move A Testament That Pharma Companies Are ...

    Benzinga
  54. The Top 5 European Stocks Held During Q3

    GuruFocus
  55. BioMarin buying Prosensa

    IBD
  56. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  57. Screening Pharma Stocks Amid Turnaround

    YCharts
  58. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus
  59. Apollo may make Glaxo offer

    IBD
  60. Irving Kahn Starts New Position In GlaxoSmithKline

    GuruFocus
  61. Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014

    GuruFocus
  62. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  63. Kahn Brothers' Third Quarter Numbers

    GuruFocus
  64. Ebola Vaccine Contenders

    Benzinga
  65. Stock Futures Upshift On Data; Yahoo, Broadcom, Boeing Climb

    IBD
  66. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  67. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  68. Sarepta Therapeutics Shares Up On Ebola Drug Safety Study

    Benzinga
  69. Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear

    IBD
  70. Ebola-Related Pharma Stocks Soar On First U.S. Case

    IBD
  71. Action Heats Up in Ebola-Related Equities

    FoxBusiness
  72. Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF

    GuruFocus
  73. Pharma Stocks: Surprising Shift In U.S. Drug Market

    YCharts
  74. Royal Bank of Scotland

    IBD
  75. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  76. International Securities For A Diversified Income Portfolio

    GuruFocus
  77. Could European Funds Offer An Opportunity Now?

    Benzinga
  78. Widely Held Guru Stocks Trading In Europe

    GuruFocus
  79. 3 Partnerships Pushing The Pharmaceutical Sector Forward

    Benzinga
  80. Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB

    GuruFocus
  81. China Fines Glaxo For Bribes

    IBD
  82. Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF

    GuruFocus
  83. Stock Futures Down, But Not Far; Alibaba Sets IPO Price Range

    IBD
  84. Benzinga's M&A Chatter for Wednesday August 27, 2014

    Benzinga
  85. GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) ...

    Benzinga
  86. InterMune Stock Spikes On Rare Big Biotech Buyout

    IBD
  87. 3 Dividend Kings From The U.K. I Love To Buy

    GuruFocus
  88. UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta ...

    Benzinga
  89. Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG

    GuruFocus
  90. Intermune up on buyout buzz

    IBD
  91. You Should Consider Adding GlaxoSmithKline Based on Tremendous ...

    GuruFocus
  92. Drugmaker AstraZeneca Returns To Growth

    IBD
  93. Widely Held Guru Stocks Near 52-Week Lows

    GuruFocus
  94. Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives ...

    Benzinga
  95. Glaxo, Sanofi Trend Up On Potential Deal For Established Brands

    Benzinga
  96. Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS

    GuruFocus
  97. Glaxo, Genmab Report Positive Interim Result for Phase III Study ...

    Benzinga
  98. A Look at the Week's Top Dividend Growers

    GuruFocus
  99. Markets Little Changed Ahead Of The Federal Reserve's Policy ...

    Benzinga
  100. GlaxoSmithKline

    IBD
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!